Example: Heart Attack

Clinical Trials Sponsored by Gilead Sciences

Total 975 results

NCT04863885

Recruiting

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Conditions: Metastatic Urothelial Carcinoma
NCT05175339

Recruiting

Long-term Impact in Intensive Care Survivors of Coronavirus Disease (COVID-19)

Conditions: COVID-19
NCT05101096

Recruiting

Study of Sacituzumab Govitecan-hziy (SG) in Japanese Participants With Advanced Solid Tumors or Triple-negative Breast Cancer

Conditions: Advanced Solid Tumors or Triple-negative Breast Cancer
NCT04827576

Recruiting

Study of Magrolimab in Participants With Solid Tumors

Conditions: Solid Tumor
NCT04617522

Recruiting

Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan-hziy in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Conditions: Advanced or Metastatic Solid Tumor, Liver Failure
NCT05489406

Not yet recruiting

Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS.

Conditions: Hiv
NCT03248479

Active, not recruiting

Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

Conditions: Hematological Malignancies
NCT02881320

Active, not recruiting

B/F/TAF FDC in HIV-1 Infected Adolescents and Children

Conditions: HIV-1 Infection
NCT03118674

Completed

Harvoni Treatment Porphyria Cutanea Tarda

Conditions: Porphyria Cutanea Tarda, Hepatitis C
NCT00885664

Completed

Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection

Conditions: HIV Infections
NCT04049617

Terminated

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors

Conditions: Advanced Solid Tumors
NCT03964727

Recruiting

Study of Sacituzumab Govitecan-hziy in Metastatic Solid Tumors

Conditions: Metastatic Solid Tumor
NCT04809623

Suspended

Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)

Conditions: Cutaneous Lupus Erythematosus
NCT03869190

Recruiting

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Conditions: Urothelial Carcinoma, Bladder Cancer
NCT05281510

Recruiting

Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women

Conditions: HIV-1-infection
NCT03960645

Active, not recruiting

Pharmacokinetic, Safety, and Efficacy of B/F/TAF in HIV-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters

Conditions: HIV-1-infection
NCT05481216

Recruiting

HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV

Conditions: HIV-1-infection, COVID-19
NCT05330429

Recruiting

Study of Magrolimab Given Together With FOLFIRI/BEV in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

Conditions: Metastatic Colorectal Cancer
NCT05327530

Recruiting

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Conditions: Locally Advanced or Metastatic Urothelial Carcinoma
NCT03926195

Active, not recruiting

Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographical Axial Spondyloarthritis
NCT03725761

Recruiting

IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Conditions: Prostate Cancer
NCT05079230

Recruiting

Study Evaluating the Safety and Effectiveness Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia (AML)

Conditions: Acute Myeloid Leukemia
NCT04530630

Recruiting

Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant

Conditions: HIV Infections, Renal Transplant Rejection
NCT03487900

Active, not recruiting

Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up

Conditions: CD
NCT03498625

Completed

Crohn's Disease Endoscopic REmission Definition in an Objective Way

Conditions: CD

Clinical Trials Sponsored by Gilead Sciences

Medical Conditions

Sponsors and Collaborators

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations